https://www.selleckchem.com/pr....oducts/lanraplenib.h
Weight management seems to be beneficial for obese atrial fibrillation (AF) patients; however, randomised data are sparse. Thus, this study aimed to investigate the influence of weight reduction on AF-ablation outcomes. SORT-AF is an investigator-sponsored, prospective, randomised, multicenter, clinical trial. Patients with symptomatic AF (paroxysmal or persistent) and Body-Mass-Index (BMI) 30-40kg/m2 underwent AF-ablation and were randomised to either weight-reduction (group-1) or usual care (group-2), after sleep-apnea-screening a
Like
Comment
Share
